subcutaneous injection Articles
-
Needles and Pills: Rani Therapeutics Is Making Encapsulated Oral Biologics
Rani Therapeutics, a clinical-stage biotherapeutics company, based in San Jose, CA, is developing orally-administered biologics. Their novel, patented platform technology replaces subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible vehicle, approximately the size of a standard fish oil or calcium pill, which is designed to automatically ...
-
Abstract 9761: Novel Modulators of Low Density Lipoprotein Receptor Metabolism
Abstract Intervention with drugs to reduce Low Density Lipoprotein-cholesterol (LDL-C) has proven to decrease the risk of subsequent cardiovascular events, including mortality. Our goal is to develop novel, small molecule, LDL-C lowering drugs by targeting the Low Density Lipoprotein Receptor (LDLR) degradation pathway, which is modulated by the protease proprotein convertase subtilisin-like ...
-
Abstract 15053: New Insights into the Development of the Protease Proprotein Convertase Subtilisin-Like Kexin Type 9 Antagonists
Abstract Protease proprotein convertase subtilisin-like kexin type 9 (PCSK9) is an important target for the treatment of hypercholesterolemia. PCSK9 is synthesized as a zymogen that undergoes autocatalytic processing and secretion. Secreted PCSK9 binds to the LDL-receptor (LDLR) and chaperones it to the degradation pathway. Several pharmaceutical companies have developed injectable mAb PCSK9 ...
-
Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately $100 ...
-
Rani Therapeutics Debuts on the Nasdaq: What uou should know About the Biopharma
IMPORTANT MESSAGE: Benzinga prides itself as a media platform that is "For the People, By the People." We understand the markets are scary right now. For that reason, we are here to help. For today only get access to our #1 Options Newsletter for only $1. Rani Therapeutics Holdings, Inc. RANI+ Free Alerts, a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq ...
-
What Is Collagen?
Collagen is a family of proteins. At least 30 kinds of genes encoding collagen chains have been found, which can form more than 16 kinds of collagen molecules. According to its structure, it can be divided into fibrous collagen, basement membrane collagen, microfibrillar collagen, anchored collagen, hexagonal reticular collagen, non-fibrous collagen, transmembrane collagen, etc. According to ...
-
Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
-
Rani developing technology for oral delivery of injectable biologics
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...
-
Raising Awareness on the Challenges of Injections: `My First Injection`
Twelve years ago Jody started getting unexplained pain, swelling and redness in her eyes after having her first child. Shortly after, she was diagnosed with Scleritis¹, a serious eye disease that is often associated with an underlying autoimmune disorder. Fast forward to today, Jody has started taking weekly injections to ease her symptoms. We sat down with Jody to hear ...
-
Rani Therapeutics offers breakthrough capsule for patients with chronic conditions
Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections. Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as neuroendocrine tumours(NETS). The company based in ...
-
A Difficult Needle to Thread
Do you know what it’s like to wake up in a different stranger’s house every morning? To open your eyes and immediately feel extremely uncomfortable, alarmed, unsafe, out of place, lost, dizzy, like your world is the most upside-down it’s ever been? Do you remember what it was like to be a kid tagging along to the grocery store with your parents? One second ...
-
Drug Delivery: What do Patients and Providers Want?
Citation: Huddleston M, Estep J, “Drug Delivery: What do Patients and Providers Want?” ONdrugDelivery, Issue 124 (Sep 2021), pp 10–14. Matthew Huddleston and Jennifer Estep discuss current drug delivery options and the value of convenient care. Worldwide, patient and provider preferences are changing due to the covid-19 pandemic. The need to reduce patient exposure to the ...
-
Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA)
ABSTRACT Previous subgroup analyses from the ACTIVE trial in women with postmenopausal osteoporosis (NCT01343004) using three-dimensional (3D)-processing of dual X-ray absorptiometry (DXA) scans indicated greater increases in total hip cortical volumetric bone mineral density (Ct.vBMD) and estimated indices of hip strength following 18 months of abaloparatide (ABL) versus placebo or ...
-
Efficacy of antimicrobial polymer coatings in an animal model of bacterial infection associated with foreign body implants
Abstract Objectives: To assess support discs, comprising polyethylene terephthalate (PET), coated with different polymer/levofloxacin combinations for antimicrobial activity in an animal model of infection, in order to explore the use of specific polymer coatings incorporating levofloxacin as a means of reducing device-related infections. Methods: Aliphatic polyester-polyurethanes ...
-
VCs infuse $215M into Sanofi-backed wearable subcutaneous drug delivery player Enable Injections
Sanofi-backed Enable Injections has gone big with its series C round. Three years after Sanofi led its series B, Enable Injections has raised a $215 million round to fund work on subcutaneous drug delivery system enFuse. Enable Injections’ device consists of a wearable delivery disc and a system for transferring the drug from its original vessel. Users put the disc in the transfer ...
-
Research Progress of Tetrahydrocurcumin
Tetrahydrocurcumin (THC), as the most active and main metabolite produced in the metabolism of curcumin in vivo, can be isolated from the cytoplasm of the small intestine and liver after curcumin administration in human or mouse. Tetrahydrocurcumin can effectively inhibit tyrosinase, inhibit the generation of Oxygen Free Radicals and scavenge the formed free radicals. It has obvious antioxidant ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you